• 1
    Shiba K, Kasahara K, Nakajima H, Adachi M. Structural changes of the airway wall impair respiratory function, even in mild asthma. Chest. 2002;122: 16226.
  • 2
    Bai TR, Knight DA. Structural changes in the airways in asthma: observations and consequences. Clin Sci. 2005;108: 46377.
  • 3
    Beckett PA, Howarth PH. Pharmacotherapy and airway remodeling in asthma? Thorax. 2003;58: 16374.
  • 4
    Van Rensen EL, Hiemstra PS, Rabe KF, Sterk PJ. Assessment of microvascular leakage via sputum induction: the role of substance P and neurokinin A in patients with asthma. Am J Respir Crit Care Med. 2002;165: 12759.
  • 5
    Haahtela T, Järvinen M, Kava T, et al. Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. N Engl J Med. 1994;331: 7005.
  • 6
    Selroos O, Pietinalho A, Löfroos AB, Riska H. Effect of early versus late intervention with inhaled corticosteroids in asthma. Chest. 1995;108: 122834.
  • 7
    Pauwels RA, Pedersen S, Busse WW, Tan WC, Chen YZ, Ohlsson SV, Ullman A, Lamm CJ, O'Byrne PM; START Investigators Group. Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. Lancet. 2003;361: 107176.
  • 8
    Laitinen A, Altraja A, Kämpe M, Linden M, Virtanen I, Laitinen LA. Tenascin is increased in airway basement membrane of asthmatics and decreased by an inhaled steroid. Am J Respir Crit Care Med. 1997;156: 9518.
  • 9
    Laitinen LA, Laitinen A. Remodeling of asthmatic airways by glucocorticosteroids. J Allergy Clin Immunol. 1996;97: 1538.
  • 10
    Holgate ST. Epithelium dysfunction in asthma. J Allergy Clin Immunol. 2007;120: 123344.
  • 11
    Chakir J, Shannon J, Molet S, Fukakusa M, Elias J, Laviolette M, Boulet LP, Hamid Q. Airway remodeling-associated mediators in moderate to severe asthma: effect of steroids on TGF-beta, IL-11, IL-17, and type I and type III collagen expression. J Allergy Clin Immunol. 2003;111: 12938.
  • 12
    Kamachi A, Munakata M, Nasuhara Y, Nishimura M, Ohtsuka Y, Amishima M, Takahashi T, Homma Y, Kawakami Y. Enhancement of goblet cell hyperplasia and airway hyperresponsiveness by salbutamol in a rat model of atopic asthma. Thorax. 2001;56: 1924.
  • 13
    Abramson MJ, Walters J, Walters EH. Adverse effects of beta-agonists: are they clinically relevant? Am J Respir Med. 2003;2: 28797.
  • 14
    Ibe BO, Abdallah MF, Raj JU. Mechanisms by which S-albuterol induces human bronchial smooth muscle cell proliferation. Int Arch Allergy Immunol. 2008;146: 32133.
  • 15
    Descalzi D, Folli C, Nicolini G, Riccio AM, Gamalero C, Scordamaglia F, Canonica GW. Anti-proliferative and anti-remodelling effect of beclomethasone dipropionate, formoterol and salbutamol alone or in combination in primary human bronchialfibroblasts. Allergy. 2008;63: 4327.
  • 16
    Wilson SJ, Wallin A, Della-Cioppa G, Sandström T, Holgate ST. Effects of budesonide and formoterol on NF-kappaB, adhesion molecules, and cytokines in asthma. Am J Respir Crit Care Med. 2001;164: 104752.
  • 17
    Wallin A, Sandström T, Söderberg M, et al. The effects of regular inhaled formoterol, budesonide, and placebo on mucosal inflammation and clinical indices in mild asthma. Am J Respir Crit Care Med. 1999;159: 7986.
  • 18
    Wallin A, Sue-Chu M, Bjermer L, Ward J, Sandström T, Lindberg A, Lundbäck B, Djukanović R, Holgate S, Wilson S. Effect of inhaled fluticasone with and without salmeterol on airway inflammation in asthma. J Allergy Clin Immunol. 2003;112: 728.
  • 19
    Wang K, Liu CT, Wu YH, Feng YL, Bai HL. Budesonide/formoterol decreases expression of vascular endothelial growth factor (VEGF) and VEGF receptor 1 within airway remodelling in asthma. Adv Ther. 2008;25: 34254.
  • 20
    Volonaki E, Psarras S, Xepapadaki P, Psomali D, Gourgiotis D, Papadopoulos NG. Synergistic effects of fluticasone propionate and salmeterol on inhibiting rhinovirus-induced epithelial production of remodelling-associated growth factors. Clin Exp Allergy. 2006;36: 126873.
  • 21
    Dahlén SE. Lipid mediator pathways in the lung: leukotrienes as a new target for the treatment of asthma. Clin Exp Allergy. 1998;28(Suppl. 5): 1416.
  • 22
    Henderson WR Jr, Chiang GK, Tien YT, Chi EY. Reversal of allergen-induced airway remodeling by CysLT1 receptor blockade. Am J Respir Crit Care Med. 2006;173: 71828.
  • 23
    Henderson WR Jr, Tang LO, Chu SJ, Tsao SM, Chiang GK, Jones F, Jonas M, Pae C, Wang H, Chi EY. A role for cysteinyl leukotrienes in airway remodeling in a mouse asthma model. Am J Respir Crit Care Med. 2002;165: 10816.
  • 24
    Bjermer L, Bisgaard H, Bousquet J, et al. Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbations in adults: one year, double-blind, randomised, comparative study. BMJ. 2003;327: 8915.
  • 25
    O'Sullivan S, Akveld M, Burke CM, Poulter LW. Effect of the addition of montelukast to inhaled fluticasone propionate on airway inflammation. Am J Respir Crit Care Med. 2003;167: 74550.
  • 26
    Gosens R, Bos IS, Zaagsma J, Meurs H. Protective effects of tiotropium bromide in the progression of airway smooth muscle remodeling. Am J Respir Crit Care Med. 2005;171: 1096102.
  • 27
    Flood-Page P, Swenson C, Faiferman I, et al., International Mepolizumab Study Group. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med. 2007;176: 106271.
  • 28
    Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med. 2003;167: 199204.
  • 29
    Flood-Page P, Menzies-Gow A, Phipps S, Ying S, Wangoo A, Ludwig MS, Barnes N, Robinson D, Kay AB. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest. 2003;112: 102936.
  • 30
    Djukanović R, Wilson SJ, Kraft M, et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med. 2004;170: 58393.
  • 31
    Plewako H, Arvidsson M, Petruson K, Oancea I, Holmberg K, Ädelroth E, Gustafsson H, Sandström T, Rak S. The effect of omalizumab on nasal allergic inflammation. J Allergy Clin Immunol. 2002;110: 6871.
  • 32
    Howarth PH, Babu KS, Arshad HS, et al. Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax. 2005;60: 10128.
  • 33
    Morjaria JB, Chauhan AJ, Babu KS, Polosa R, Davies DE, Holgate ST. The role of a soluble TNFalpha receptor fusion protein (etanercept) in corticosteroid refractory asthma: a double blind, randomised, placebo controlled trial. Thorax. 2008;63: 58491.
  • 34
    Berry MA, Hargadon B, Shelley M, Parker D, Shaw DE, Green RH, Bradding P, Brightling CE, Wardlaw AJ, Pavord ID. Evidence of a role of tumor necrosis factor alpha in refractory asthma. N Engl J Med. 2006;354: 697708.
  • 35
    Saetta M, Maestrelli P, Di Stefano A, De Marzo N, Milani GF, Pivirotto F, Mapp CE, Fabbri LM. Effect of cessation of exposure to toluene diisocyanate (TDI) on bronchial mucosa of subjects with TDI-induced asthma. Am Rev Respir Dis. 1992;145: 16974.
  • 36
    Sumi Y, Foley S, Daigle S, L'Archevêque J, Olivenstein R, Letuvé S, Malo JL, Hamid Q. Structural changes and airway remodelling in occupational asthma at a mean interval of 14 years after cessation of exposure. Clin Exp Allergy. 2007;37: 17817.
  • 37
    Dharmage S, Walters EH, Thien F, Bailey M, Raven J, Wharton C, Rolland J, Light L, Freezer N, Abramson M. Encasement of bedding does not improve asthma in atopic adult asthmatics. Int Arch Allergy Immunol. 2006;139: 1328.
  • 38
    Woodcock A, Forster L, Matthews E, et al.; Medical Research Council General Practice Research Framework. Control of exposure to mite allergen and allergen-impermeable bed covers for adults with asthma. N Engl J Med. 2003;349: 22536.
  • 39
    Cox PG, Miller J, Mitzner W, Leff AR. Radiofrequency ablation of airway smooth muscle for sustained treatment of asthma: preliminary investigations. Eur Respir J. 2004;24: 65963.
  • 40
    Brown RH, Wizeman W, Danek C, Mitzner W. In vivo evaluation of the effectiveness of bronchial thermoplasty with computed tomography. J Appl Physiol. 2005;98: 16036.
  • 41
    Brown RH, Wizeman W, Danek C, Mitzner W. Effect of bronchial thermoplasty on airway distensibility. Eur Respir J. 2005;26: 27782.
  • 42
    Cox G, Thomson NC, Rubin AS, et al.; AIR Trial Study Group. Asthma control during the year after bronchial thermoplasty. N Engl J Med. 2007;356: 132737.
  • 43
    Balzar S, Wenzel SE, Chu HW. Transbronchial biopsy as a tool to evaluate small airways in asthma. Eur Respir J. 2002;20: 2549.
  • 44
    Aysola RS, Hoffman EA, Gierada D, et al. Airway remodeling measured by multidetector CT is increased in severe asthma and correlates with pathology. Chest. 2008;134: 118391.
  • 45
    Corren J. Small airways disease in asthma. Curr Allergy Asthma Rep. 2008;8: 5339.